CardioSignal, a Turku, Finland- and Palo Alto, CA-based provider of solutions for the detection of heart diseases using digital cardiac biomarkers, raised $10M in Series A funding.
The round, which brought the total amount to $23M, was led by DigiTx Partners, with participation from Sandwater and existing investor Maki.vc.
The company intends to use the funds to further clinical validation of its technology and the expansion of its commercial efforts.
Led by CEO and Founder Dr. Juuso Blomster, CardioSignal develops solutions for the detection of heart diseases using digital cardiac biomarkers. Its technology utilizes the gyroscope and accelerometer motion sensors to non-invasively measure heart motion to determine cardiac health and function. Currently, CardioSignal’s technology produces digital biomarkers validated in clinical studies for Atrial fibrillation (A-fib) and Heart failure, with additional development ongoing for Aortic stenosis, Coronary artery disease, and Pulmonary artery hypertension. The application is already available in 15 countries as a class IIa medical device for detecting signs of Atrial fibrillation.
Commenting on the news, Juuso Blomster said: “More than 20 million people die each year from cardiovascular diseases. This funding enables us to scale a detection and remote monitoring solution for primary care doctors and their patients. Currently, primary care has very limited tools to detect heart diseases, like heart failure patients who are often already experiencing symptoms. We can support the shift in cardiovascular care from treating complications to earlier detection and prevention.”
FinSMEs
23/01/2024